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The initial pharmaceutical interest for the endocannabinoid system as a target for antiobesity therapies has been restricted by
the severe adverse effects of the CB1 antagonist rimonabant. This study points at oleoylethanolamide (OEA), a monounsaturated
analogue, and functional antagonist of anandamide, as a potential and safer antiobesity alternative to CB1 antagonism.Mice treated
with equal doses (5 or 10mg/kg, i.p.) of OEA or rimonabant were analyzed for the progressive expression of spontaneous behaviors
(eating, grooming, rearing, locomotion, and resting) occurring during the development of satiety, according to the paradigm
called behavioral satiety sequence (BSS). Both drugs reduced food (wet mash) intake to a similar extent. OEA treatment decreased
eating activity within the first 30min and caused a temporary increase of resting time that was not accompanied by any decline of
horizontal, vertical and total motor activity. Besides decreasing eating activity, rimonabant caused a marked increase of the time
spent grooming and decreased horizontal motor activity, alterations that might be indicative of aversive nonmotivational effects on
feeding. These results support the idea that OEA suppresses appetite by stimulating satiety and that its profile of action might be
predictive of safer effects in humans as a novel antiobesity treatment.
1. Introduction
Despite the continuous increase of obesity incidence in all
developed countries, limited pharmacological therapies are
currently available to treat obesity in an efficacious and
safe manner. Thus, development of effective and safe anti-
obesity therapies is a priority for both patients and health
systems. Efficacy and safety are the ideal endpoints of anti-
obesity medications that should put together the ability to
suppress food intake and reduce fat depots with the increase
of nutrients oxidation and lack of major side effects burden.
One of the most promising novel pharmacological targets
for drug development is the endocannabinoid (EC) system
and its related compounds, theN-acylethanolamines (NAEs).
Among the latter ones, anandamide represents the most
studied compound mainly for its ability to act as endogenous
ligand for cannabinoid receptor type 1 (CB1). A large body
of evidence has clearly demonstrated that the stimulation
of this receptor exerts powerful effects on energy balance,
increasing appetitive drive and promoting adiposity [1, 2].
Therefore, several CB1 receptor antagonists have been tested
in both genetic and dietary rodent models of obesity for
their potential effects as antiobesity treatments [3–9]. One of
these compounds, rimonabant (also referred as SR141716A)
reached the market after successful clinical trials, which
confirmed the observations made in rodents on its efficacy in
body weight reduction and in the metabolic benefits induced
in obese subjects [10, 11]. However, the emergence of severe
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psychiatric adverse effects, mostly attributable to the inverse
agonistic activity of rimonabant at central CB1 receptor, led
to its withdrawal from the market [12, 13]. Such drawbacks
led to a reassessment of the potential of the EC system as a
drug target for novel antiobesity therapy aimed at preventing
the severe side effects induced by central CB1 receptors
blockade. Several reports have been indicating as possible
safer pharmacological alternatives to rimonabant a number
of novel “neutral” or “silent” CB1 receptor antagonists, such
as AM4113, peripherally restricted CB1 receptor antagonists,
such as AM6545, LH-21, MJ15, URB447 [14], CB1 receptor
partial agonists, allosteric modulators of CB1 receptors, and
other agents able to alter EC levels [15].
In this context, increasing interest has been focusing also
on a group of NAEs that are AEA congeners but seem to
act through mechanisms independent of CB1 receptors. This
group includes the monounsaturated analogue oleoyletha-
nolamide (OEA) [16, 17], which, although sharing similar
biosynthetic pathways [18] with AEA, exerts opposite effects
on feeding regulation and lipid metabolism. AEA binds with
high affinity the CB1 [19] and its administration induce
hyperphagia that can be attenuated or abolished by CB1
receptor blockade [20–23]. In contrast to AEA, OEA does not
have any affinity for CB1 receptor and its systemic admin-
istration inhibits food consumption in rodents by delaying
eating onset. Recent studies on the physiological role of OEA
demonstrated that it may act as a gut-derived satiety factor
(for review: [16, 17, 24, 25]). In particular, OEA is synthesized
in the upper part of the small intestine, upon the absorption of
lipids from the diet [26–28]. OEA binds with high affinity the
nuclear receptor peroxisome proliferator-activated receptor
𝛼 (PPAR-𝛼) [29] to control the expression of several genes
involved in fat absorption and fatty acid metabolism, to
activate hypothalamic oxytocinergic neurons and to inhibit
further eating [29–32].These effects were observed in rodents
when OEA was systemically administered at dosages ranging
from 5 to 20mg/kg [32, 33], with an ED50 = 9.2 ± 1.6mg/kg,
i.p. [34].
Accumulating evidence suggests that OEA might be
involved in different pathophysiological aspects of appetite
and metabolism regulation. For example, elevated OEA con-
centration has been described in plasma and cerebrospinal
fluid of woman affected by eating disorders [35], in the saliva
of obese subjects [36], and in the subcutaneous adipose
tissue of subjects with both obesity and type 2 diabetes [37].
Conversely, decreased OEA intestinal content was observed
in rodent models of obesity [38–40]. These findings might
suggest that excessive or altered food intake may render
the mechanism dysfunctional, raising the possibility that
OEA might represent a novel pharmacological target to treat
such pathologies. This hypothesis is supported by several
observations made on obese rodent models in which OEA
decreased hyperphagia and body weight gain, increased
lipolysis, and decreased hypertriglyceridemia, hypercholes-
terolemia, and liver steatosis, when chronically administered
thus demonstrating a significant effect not only on the acute,
short-term—but also on the long-term appetite and energy
regulation [31, 41–45]. Moreover, the link between dietary fat
intake and OEA’s action on feeding behaviour and obesity
has been recently strengthened by the finding that OEA
subchronic treatment can reestablish a normal response of
the brain reward system to an intraduodenal infusion of lipids
that seems to be altered in diet-induced-obese mice [46].
Since similar reward hypofunctionality has been described in
obese subjects and has been proposed as part of the central
mechanism sustaining hyperphagia, this finding suggests a
potential therapeutic relevance of OEA in food addiction
[46]. Based on these considerations, in this study we propose
OEA as a possible pharmacological alternative to anorexiant
and/or antiobesity drugs targeting CB1 receptors. To test our
hypothesis we compared the acute effects of OEA with those
of rimonabant on spontaneous behaviors observed in mice
during the beginning of the consummatory phase of their
daily activities, as assessed in the paradigm of the behavioral
satiety sequence (BSS).
The commonest dependent variable recorded in animal
studies aimed at understanding drug effects on feeding is
the amount of food eaten by the animals [47]. However,
food intake and feeding behavior can be affected by several
factors, including those acting in nonspecific manners, such
as pain, stress, anxiety, and nausea.Therefore, one of themost
contentious issues in the psychopharmacology of appetite
regulation is the identification of the physiologicmechanisms
underlying the observed reduction of eating. Animals cannot
report their aversive side effects and the maintenance of a
normal feeding structure in strings of behavioral acts may
be used to verify drug effects on the normal physiology of
appetite regulation.TheBSS is an observational approach that
allows investigating the effects of drugs acting on feeding
by examining the presence of an orderly progression of
behavioral patterns from eating to grooming and finally to
resting, as it is typically observed in the rodent spontaneous
behavior during the development of satiety [48, 49]. As
previously underlined [50, 51], since the BSS relies on the
animal’s spontaneous pattern of feeding, this paradigm helps
to circumvent several problems of model validity associated
to other testing procedures.
In previous studies, the analysis of BSS in rats treated
with rimonabant has revealed that this compound preserves
the order of events and, nevertheless, differs markedly from
the natural satiation. The most notable difference is that
grooming (particularly scratching) is profoundly enhanced
at anorectic doses, while eating and resting are diminished,
raising the possibility that anorectic effect is simply sec-
ondary to the grooming effect [50, 52]. Recent evidence
does not appear to support this hypothesis, showing that
the acute anorectic response induced by rimonabant cannot
be just accounted by the time spent in grooming behavior
[14, 53]. Moreover, excessive grooming in rodents may be
indicative of an altered emotional state induced by rimona-
bant administration. This hypothesis has been confirmed by
specific behavioral tests in rodents and by clinical observa-
tions showing that rimonabant is an anxiogenic compound
[54, 55].
On the other hand, several clues suggest that the anorexi-
ant actions of OEA are not attributable to stress or malaise.
In fact, it has been shown that OEA does not elicit fear or
anxiety-like behaviors, does not affect plasma corticosterone
BioMed Research International 3
levels, and does not induce conditioned taste aversion in
rats [31]. Moreover, by the meal pattern analysis of animals
subjected to the acute OEA treatment, we previously demon-
strated that OEA selectively delays the normal eating onset
in free-feeding rats and mice without affecting meal size and
postmeal interval, suggesting that this lipid mediator may
participate in the physiological control of satiety [32]. How-
ever, whether OEA can affect other spontaneous behaviors
related to eating, such as those analyzed in the BSS paradigm,
remained unexplored [33].
Therefore, in this study we evaluated the behavioral
profile of mice that underwent acute administration with
either OEA or rimonabant, by focusing on the occurrence
of spontaneous behaviors typically investigated via the BSS
paradigm. Per each compound we tested two different doses
(i.e., 5 or 10mg/kg, i.p.), based on the results of our previous
acute dose-response studies [32–34] on OEA’s anorexiant
effects. Both OEA doses were previously demonstrated to
be sufficient to activate fully PPAR-𝛼 [29]. The dosages of
rimonabant were chosen to obtain an acute inhibition of food
intake in mice that could be similar to that elicited by OEA
treatment. These doses are consistent with previous studies
[4, 56–59] showing that they can lead to more than 95% of
brain CB1 receptor occupancy [60].
2. Materials and Methods
2.1. Animals and Housing. All experiments were carried out
onmale C57BL6/J inbredmice that were generously provided
by the CNR-EMMA animal facility (Monterotondo, Rome,
Italy). Mice, 9-week-old, weighing 26± 0.5 g at the beginning
of the experiments, were housed individually in breeding
cages (26.7 × 20.7 × 14 cm) in a room with humidity control
and constant temperature (22 ± 1∘C) on a 12 h light/dark
cycle (lights off 7:00 PM). Animals had ad libitum access to
standard diet (4RF21; Mucedola s.r.l., Milan, Italy) and water.
Thirty-eightC57BL6/Jmicewere used for the study of feeding
behavior via the BSS protocol. Housing, animalmaintenance,
and all experiments were performed in accordance with the
Council Directive of the European Community (86/EEC)
of the Italian D.L. 116 (January 27, 1992) and approved by
veterinarian supervision.
2.2. Drugs. N-Piperidino-5-(4-chlorophenyl)-1-(2,4-dichlo-
rophenyl)-4-methyl-pyrazolecarboxamide (rimonabant) and
(9Z)-N-(2-hydroxyethyl)octadec-9-enamide (OEA) were
dissolved in 5% Tween—80/5% polyethylene glycol/saline
(by volume) and injected intraperitoneally (i.p.) in a volume
of 10mL/kg of body weight. Rimonabant and OEA were
purchased from Cayman Chemical (Ann Arbor, Michigan
48108, USA). All HPLC chemicals were from Sigma-Aldrich
(Milan, Italy).
2.3. Habituation to Wet Mash. Before the start of BSS, mice
were habituated for 10 days to the special diet used during
the behavioral satiety sequence procedure (see below), which
consists in a nonsweetened wet meal (i.e., wet mash, WM)
that was always prepared fresh on a daily basis. In particular,
wet mash was made up of a mixture of one-part ground stan-
dard dry powdered food pellets to 2.5 parts distilled water,
during both habituation and BSS testing. Powdered food was
obtained by the standard maintenance diet (4RF21 diet) that
provides an energy value of 3.95 Kcal/g. The use of hydrated
food orWM as test diet has been acknowledged in the BSS by
several studies and procedures [61–63]. WM provides higher
than standard diet palatability also in its nonsweetened
form. The increase in palatability provides higher mean diet
intake as compared to nonhydrated food and its consistency
permits to minimize spillage, thus allowing a more accurate
estimation of food intake. Although spillage is maximally
curtailed by WM texture, its possible occurrence was always
checked at the end of each observational period. WM was
provided in small opaque plastic beakers (3 cm diameter)
mounted on a plastic Petri dish [48], further reducing the
possibility that WM is consumed in a different place. During
the habituation phase, WM was offered for 2 h/day during
daylight period (4:00–6:00 PM) up to the day before drug
treatment and BSS testing. During the habituation to WM
consumption, both body weight (g) and food intake (g) were
measured daily (data not shown). The intake of wet mash
was the difference between the weight of WM-containing
food dispenser immediately before themeal presentation and
the remaining food collected and recorded after 2 h. The BSS
analysis was performed only in case WM daily consumption
stabilized over the course of the habituation period, thus
preventing the risk of neophobic reactions.
2.4. Drug Treatment and Behavioral Satiety Sequence (BSS).
According to a former analytic description of the BSS proce-
dure [51], all the behavioral patterns were monitored contin-
uously and not coded or collected by a sampling technique.
The duration (sec) of the behavioral patterns (i.e., time spent
in a selected behavior) was recorded for each subject and
separately scored, as follows: eating activity (mouse leaned
on food dispenser biting, chewing, or holding food in paws),
grooming (face and body cleansing, i.e., mouse scratching
its face with its forepaws, licking or biting the coat), resting
(total immobility), locomotion (horizontal motor activity),
rearing (mouse completely erected on its hind legs), and
total motor activity (horizontal activity and rearing). BSS-
associated behaviors were recorded in animals’ home cages,
thus avoiding the need of preliminary habituation to the
testing environment to minimize novelty-induced anxiety.
Trained observers blind to the experimental conditions
performed the behavioral scoring. Mice were fasted for 12 h
(08:00AM–08:00 PM) and the evolution of BSSwas recorded
during the dark cycle (08:00 PM-09:00 PM) in a soundproof
cubicle equipped with an infrared night-vision video record-
ing camera (Panasonic color CCTV Camera WV-CP310/G).
On the basis of a number of studies documenting the mean
interval of satiety progression in rodents [48, 51, 64], the
procedure was stopped after 45min. This testing duration
matches the timewindowdescribed in the analysis of a typical
BSS experimental protocol [62] that designates 40min of
feeding during the light-off phase as the time interval during
which rodents ingest the most part of their daily food intake
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Figure 1: (a) and (b) show, respectively, mean cumulative wet mash intake (±S.E.M) andmean time spent in eating activity (±S.E.M) by mice
treated with vehicle, OEA 5mg/kg i.p. (OEA 5), rimonabant 5mg/kg i.p. (R 5), OEA 10mg/kg i.p. (OEA 10), and rimonabant 10mg/kg, i.p.
(R 10) over the 45min BSS, (𝑛 = 6 vehicle group and 𝑛 = 8 both doses of rimonabant and OEA-treated mice). ∗𝑃 < 0.05 versus vehicle;
#
𝑃 < 0.05 versus OEA 5 (Tukey HSD test).
and the effects of anorectic agents can be better quantified.
The testing duration of BSS is compatible with (i) the duration
of OEA’s anorexiant action that was previously reported to be
evident for 1 h after treatment at the same doses used in the
present study, (ii) the maximum plasma levels concentration
of OEA (at either 5mg/kg or 10mg/kg) detected 30min after
its administration [32, 34, 65], and (iii) the in vivo half-life
of 118.9 (±66.1)min of rimonabant, when administered at
1mg/kg [66].
Immediately before wet mash presentation, mice were
administered with one of the following treatments: OEA
(either 5 or 10mg/kg, i.p.; 𝑁 = 8 and 𝑁 = 8, resp.), rimo-
nabant (either 5 or 10mg/kg, i.p.;𝑁 = 8 and𝑁 = 8, resp.), or
vehicle (10mL/kg, i.p.;𝑁 = 6). Mice were given a preweighed
amount of wet mash with the difference between initial and
final weights corresponding to wet mash intake.
2.5. Data Analysis. Statistical analysis was performed using
StatSoft, Inc. (2007) STATISTICA, version 8.0.
The total amount of wet mash consumed by animals
during the 45min observation period was analyzed by one-
way ANOVA. The same statistical analysis was adopted to
analyze the total duration of eating activity during the 45min
period. To analyze behavioral changes during the BSS, the
45min continuous recording for each behavioral category
was partitioned in 3 × 15min time intervals. OEA and
rimonabant effects on the duration of each BSS behavior
were assessed by two-way repeated measures ANOVAs with
treatment (5 levels, comprising two doses per drug and one
vehicle group) as between-subject variable and time (3 levels,
including 3 time intervals of 15min each) as within-subject
variable. All post hoc comparisons were carried out by Tukey
HSD test. The criterion value for all statistical tests was 𝑃 <
0.05.
3. Results
3.1. Effects of OEA and Rimonabant Administration on Wet
Mash Intake and Time Spent Eating. Theone-way ANOVA of
the total amount of wet mash consumed showed a significant
effect of treatment (𝐹
4,33
= 37.50, 𝑃 < 0.0001). The post
hoc analysis revealed that both drugs affected this parameter
to a similar extent (Figure 1(a)). More specifically, a dose-
dependent inhibition of mash intake was observed after
OEA administration, while rimonabant treatment similarly
inhibited feeding at both dosages (Figure 1(a)). Treatments
affected also the total time spent eating, as revealed by
the one-way ANOVA of the eating activity over the 45min
observation period (𝐹
4,33
= 30.09, 𝑃 < 0.0001). The post hoc
test demonstrated that both drugs at both dosages similarly
affected this parameter (Figure 1(b)).
3.2. Effects of OEA and Rimonabant Administration on the
Behavioral Satiety Sequence Pattern. Two-way ANOVA anal-
ysis revealed a significant treatment effect on eating activity
(𝐹
4,33
= 30.09, 𝑃 < 0.0001) during the 45min BSS testing.
A significant treatment × time interaction (𝐹
8,66
= 615.46,
𝑃 < 0.00001) was also found. Post hoc comparisons revealed
a significant decrease of eating activity (Figure 2(a)) in OEA
(5 and 10mg/kg; both 𝑃 < 0.001) and rimonabant (5 and
10mg/kg; both𝑃 < 0.001) groups, as compared to controls, at
15 and 30min time intervals. The reduction in eating activity
was still evident for rimonabant at 45min at both doses
(5 and 10mg/kg; both 𝑃 < 0.005). The ANOVA analysis
demonstrated a significant treatment effect on grooming
(𝐹
4,33
= 65.02, 𝑃 < 0.0001) as well as a significant
treatment × time interaction (𝐹
8,66
= 2.13, 𝑃 < 0.05).
Post-hoc comparisons showed that rimonabant significantly
increased grooming at both doses (5 and 10mg/kg; 𝑃 <
0.001) whatever the time interval considered, while OEA
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never affected the total time spent in grooming activity
(Figure 2(b)). Concerning the time spent in resting, two-
way ANOVA analysis evidenced a significant treatment effect
(𝐹
4,33
= 5.73, 𝑃 < 0.01) and a significant treatment ×
time interaction (𝐹
8,66
= 4.85, 𝑃 < 0.0001). As further
revealed by the post hoc analysis, with the exception of
a significant and temporary (present only at the second,
30min, time interval) increase in the time spent in resting
in animals treated with OEA (10mg/kg), no other significant
changes were detected (Figure 2(c)). Concerning locomotion
(horizontal motor activity, Figure 2(d)), the ANOVA analysis
disclosed a significant treatment effect (𝐹
4,33
= 21.14, 𝑃 <
0.0001) and a significant treatment× time interaction (𝐹
8,66
=
13.74, 𝑃 < 0.0001). Post hoc comparisons showed that
horizontal motor activity was decreased at 15min interval
in animals administered with rimonabant (10mg/kg; 𝑃 <
0.001), after 30min interval in animals that received both
doses of rimonabant (5 and 10mg/kg; 𝑃 < 0.01 and 𝑃 <
0.005, resp.), while no significant changes were detected
at the last time interval considered (45min, Figure 2(d)).
Moreover, two-way ANOVA analysis showed a significant
treatment effect on rearing (𝐹
4,33
= 8.75, 𝑃 < 0.0001) and
a significant treatment × time interaction (𝐹
8,66
= 4.24, 𝑃 <
0.001). Post hoc analysis evidenced that none of the drugs
studied significantly affected the rearing activity. As showed
(Figure 2(e)), although there was a tendency for rimonabant
(10mg/kg) to reduce rearing this reduction did not result
significant. Finally, the ANOVA analysis on the total motor
activity (Figure 2(f)) evidenced a significant main treatment
effect (𝐹
4,33
= 22.64, 𝑃 < 0.0001) and a significant treatment
× time interaction (𝐹
8,66
= 4.64, 𝑃 < 0.0001). Post hoc
comparisons further showed that rimonabant induced a clear
tendency to reduce total motor activity during the first time
interval that became significant during the first time interval
(15min; 10mg/kg; 𝑃 < 0.01). Such decrease of total motor
activity was evidenced also for the lower dose of rimonabant
in the second (30min) time interval (5mg/kg; 𝑃 < 0.01)
(Figure 2(f)), while none of the drugs tested affected the
whole motricity at the final time interval (45min) analyzed
(Figure 2(f)).
4. Discussion
Themain finding of this study is that systemic administration
of the same dosages of OEA or rimonabant produces similar
anorexiant effects but different effects on other spontaneous
behaviors related to feeding, such as grooming and resting.
These similarities and differences may be of therapeutic
relevance, since they might suggest that OEA is a possible
pharmacological alternative to the CB1 antagonism/inverse
agonism that might be devoid of the adverse effects observed
with rimonabant.
Specifically, our results demonstrate that both drugs
significantly reduced wet mash intake to a similar extent,
with a clear dose-response fashion for OEA. This decrease
was due to an overall similar decrease of eating activity
recorded in the 45min observation period. However, at the
same time, the two drugs differed for the effects on other
behaviors analyzed. In particular, grooming behavior was
significantly affected by rimonabant treatment that caused
a marked increase of the time spent in grooming through-
out the 45min period of observation (Figure 2(b)). Thus,
although for the OEA-mediated effects the decrease of eating
activity was less persistent than rimonabant, the general
increase in grooming induced by rimonabant was identified
all over the 45min and no differences in the whole eating
activity between the two drugs were detected (Figure 1(b)).
Moreover, the grooming increase was paralleled by a decrease
of locomotion (Figure 2(d)) and general activity (Figure 2(f))
particularly evident in mice treated with the highest dose
of rimonabant. OEA treatment, besides decreasing eating
activity within the first 30min of observation, caused also
a delayed increase (evident at 30min) of the time spent
resting in mice treated with the highest dose (Figure 2(c)).
However, such increasewas not accompanied by any decrease
of horizontal (locomotion), vertical (rearing), and totalmotor
activity whatever the dose tested.
The effects of rimonabant on grooming behavior in
rodents have been described in the literature with similar
observations made also for the preclinical effects of other
CB1 receptor antagonists/inverse agonists and even newer
neutral CB1 receptor antagonists [50, 53]. In particular several
studies described a syndrome of compulsive scratching and
grooming in rodents as well as severe itching and scratching
in humans [14, 67, 68]. Initially such effects were considered
to be responsible for the anorexiant actions of the drugs, due
to a sort of response competition between eating and groom-
ing/scratching behaviors. However, it has been demonstrated
that the two actions are independent and probably mediated
by the interactions of rimonabant with different (central
versus peripheral) receptors and the involvement also of other
mechanisms such as the activation of opioid receptors [14].
In our study we did not focus on scratching behaviour but
did record an intense compulsive grooming in mice treated
with rimonabant that gave us the idea of a competitive behav-
ior able to interfere with eating activity. However, testing this
hypothesis was beyond the aim of our experiments.
Compulsive grooming in mice has an important etholog-
ical relevance. It is particularly sensitive to stress and might
indicate an altered emotional reactivity of the animal [69].
The stimulation of grooming behavior caused by rimonabant
treatment is compatible with its anxiogenic effects observed
in several animal models [54]. By contrast, this effect was
completely absent in animals treated with OEA. We previ-
ously demonstrated that OEA decreases food intake in free-
feeding rodents by causing a dose-dependent delay in eating
onset, which is not accompanied by changes in meal size
or postmeal interval [32]. This delay cannot be attributed to
motoric inhibition, because it occurs at doses of OEA (5–
10mg/kg) that have no effect on either locomotor activity
in the open field test or operant responding for food [31].
Furthermore, the OEA-induced delay in feeding is unlikely
to be caused by anxiety or malaise since OEA does not alter
rodent performance in the elevated plus-maze test or produce
conditioned taste aversion for saccharin [31].
OEA actions seem to be associated with the activation of
PPAR-𝛼 receptors, as its anorexiant effects, as well as those
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Figure 2: Panels illustrate the temporal development (duration of each behavior in sec) of eating (a), grooming (b), resting (c), horizontal
motor activity (d), rearing activity (e), and totalmotor activity (f) inmice treatedwith vehicle, OEA 5mg/kg i.p. (OEA 5), rimonabant 5mg/kg
i.p. (R 5), OEA 10mg/kg i.p. (OEA 10), and rimonabant 10mg/kg, i.p. (R 10). Represented on the x-axes are 3 time intervals of 15min each for
a total of 45min of BSS analysis. Experiments were carried out during light-off period (08:00 PM-09:00 PM). ∗𝑃 < 0.05 versus vehicle group
for each time interval (Tukey HSD test).
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reported on the meal pattern, have not been observed in
PPAR-𝛼 null mice [29]. Other possible receptors suggested
to be involved in OEA’s actions are the capsaicin receptor
TRPV1 and the G protein coupled receptor GPR119 [70–72].
However, the observation that genetic deletion of TRPV1 or
GPR119 in mice does not prevent OEA anorexiant actions
[41, 73], as observed in mice lacking PPAR-𝛼 receptors
[29], strongly supports the hypothesis that PPAR-𝛼 receptors
mediate OEA effects on feeding behaviour.
Peripheral rather than central PPAR-𝛼 receptors seem
to be particularly involved. This hypothesis is supported by
the observation that OEA anorexiant action is completely
absent when peripheral sensory fibers are removed by cap-
saicin treatment, by surgical dissection or when the drug is
injected into the brain ventricles [31]. However, OEA can
still inhibit feeding when locally infused in the rat lateral
hypothalamus [74] and OEA and PPAR-𝛼 can be found in
the brain, where they play a role in the modulation of several
functions including cognition [75] drug and food reward
[46, 76] neuroprotection [77] and sleep-waking cycle [74].
Nevertheless, the finding that systemic administration of
OEA is not followed by increased levels of the drug in the
brain [78] suggests that peripheral and central compartments
of OEA distribution are kept separated. This is presumably
attributable to the high expression of its degrading enzyme,
fatty acid amide hydrolase, in the blood-brain barrier [79].
The same enzyme is responsible also for the degradation
of AEA, which in many of the cited functions of OEA may
be seen as a functional antagonist.This is particularly evident
for the modulation of food intake and lipid metabolism, for
which AEA and OEA play two opposite roles: AEA stim-
ulates appetite and promotes lipogenesis and body weight
gain, while OEA inhibits appetite, stimulates lipolysis, and
decreases body weight gain.
5. Conclusions
Based on these considerations, the results of the present
study corroborate the idea that OEA [24, 25, 80] might
represent a novel anorexiant agent sharing with rimonabant
similar powerful effects on food intake but not the same
impact on feeding behavior. In contrast to rimonabant, OEA
does not block CB1 receptors and is not accountable for
the wide spectrum of unwanted effects typically observed
with CB1 antagonists/reverse agonists, whereas, by acting as
a functional antagonist, it might counteract the actions of
ECs on appetite stimulation and on the control of energy
balance. We have recently showed that OEA administration
can induce satiety by indirectly stimulating oxytocin neu-
rosecretion from the hypothalamus [30, 81, 82], thus further
supporting the notion that OEA or OEA-related compounds
might represent a novel and safer antiobesity agent [83,
84] targeting systems other than those controlled by CB1
activation/blockade.
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